1. Home /
    2. Altai Protocol Library /
  2. New Indication: Pralsetinib for advanced RET-mutated medullary thyroid cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Pralsetinib for advanced RET-mutated medullary thyroid cancer

New Indication: Pralsetinib for advanced RET-mutated medullary thyroid cancer
Study:
  • Phase I/II, single arm (ARROW trial)
  • Advanced RET mutation-positive medullary thyroid cancer (MTC, n= 79). Previously treated with cabozantinib or vandetanib or both (n=55)
Efficacy:
  • ORR: 65% (overall, 53%-75%), 60% (previously treated, 46% – 74%)
  • 18-mo PFS: 71% (previously treated, 58% – 85%)
  • Responses occurred regardless of RET mutation genotype (somatic or germline)
Safety:
  • Grade 3-4 AEs: Neutropenia (16%), hypertension (14%), hypophosphatemia (11%), pneumonia (8%), interstitial lung disease (3%)

Annals of Oncology (2020) 31 (suppl_4)

Hu M, et al. Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)

https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More